A More Complete Picture of Antibody Function: Lessons from Comprehensive Fc Profiling of Approved Anti-CD20 Antibodies

Date:

September 15, 2026

Time (ET):

11:00 am

Duration (min):

CD20 is one of the most clinically validated targets for therapeutic antibody development, with approved therapies spanning both oncology and autoimmune disease. While Rituximab, Ofatumumab, and Obinutuzumab have been studied extensively, much of their Fc-mediated biology has been characterized using a relatively limited set of assays. In this webinar, we'll present a comprehensive head-to-head comparison of these three antibodies to explore how evaluating Fc biology in the presence of antigen and across multiple primary human immune cell types can provide a more complete picture of antibody function, helping researchers make more informed decisions during antibody characterization, Fc engineering, and lead selection.

Using a near-native CD20 virus-like particle (VLP) antigen, we'll show how this approach confirms well-established mechanisms of action while uncovering additional Fc-mediated immune pathways involving neutrophils, eosinophils, and dendritic cells. We'll discuss what these findings reveal about antibody biology and how comprehensive Fc profiling can support more informed therapeutic antibody development.

Learning Objectives

Understand the impact of antigen context on antibody function.
Explore Fc-mediated mechanisms beyond traditional ADCC and CDC.
Recognize the value of profiling antibodies across multiple primary human immune cell types.
Evaluate how comprehensive Fc profiling can inform lead selection and Fc engineering.

専門家の見解：

Amanda Gross

PhD

SeromYx Systems

Associate Director, Immunology

Amanda Gross, Ph.D., Associate Director, Immunology,has over seven years of industry experience, specializing in antibodycharacterization and functional profiling. At SeromYx Systems, she plays a keyrole in managing and executing studies that leverage advanced, antigen-specificassays to better understand antibody function beyond binding. Amanda earned herPh.D. from Tufts University and is passionate about applying translationalimmunology to support vaccine and therapeutic development.

スポンサー：

KACTUS

コンテンツを探す

At KACTUS, we specialize in high-activity recombinant proteins and enzymes to accelerate drug and therapeutic development. Our 3,000+ product catalog covers a variety of protein, species, tags, and labels. These rigorously tested products can be applied to a variety of research and drug development areas including antibody drug discovery, cell therapy, gene therapy, and mRNA therapeutics. Each product undergoes strict quality control for purity, performance, consistency, and stability of supply. We've developed an expertise in difficult-to-express proteins, including being the first to recombinantly produce full-length Claudin 18.2 protein. Since then, we've developed a large catalog of multipass transmembrane proteins, MHC complexes, and other challenging proteins and enzymes. Researchers also value our custom protein expression services, owing to our demonstrated expertise in complex protein expression and responsive support.

https://kactusbio.com/

トピック

Antibodies

In Vitro Assays

Cell Culture & Characterization

Pharmacology

Protein Sciences

A More Complete Picture of Antibody Function: Lessons from Comprehensive Fc Profiling of Approved Anti-CD20 Antibodies

Learning Objectives

専門家の見解：

Amanda Gross

PhD

スポンサー：

KACTUS

トピック

今すぐ視聴する

関連コンテンツ

Advancing Metabolic Disease Drug Development: Translational Models and a GLP-1 Receptor Agonist Metabolism Case Study

Improving Translational Decision-Making through Disease-Relevant Preclinical Models in Pulmonary Fibrosis and Pain Drug Discovery

Protein Complex Biomarkers: Quantify NLRP3 Inflammasome Assembly and Activity Levels from Clinical Samples

Non CYP Mediated Metabolism Pathways and In Vitro Evaluation Strategies

Human Biological Samples in Research: Quality, Compliance, and Clinical Relevance

Beyond Checkpoints: Strategic Use of CDX Models in Emerging IO Therapies

Smarter Drug Discovery: Turning Screening Hits into Opportunities

Improving Translational Decision-Making through Disease-Relevant Preclinical Models in Pulmonary Fibrosis and Pain Drug Discovery

Advancing Metabolic Disease Drug Development: Translational Models and a GLP-1 Receptor Agonist Metabolism Case Study

Protein Complex Biomarkers: Quantify NLRP3 Inflammasome Assembly and Activity Levels from Clinical Samples

Building New Approach Methodologies (NAMs) and Complex In Vitro Assays

From Skull to Deep Brain: Exploring Brain Dynamics with Intravital Imaging

A More Complete Picture of Antibody Function: Lessons from Comprehensive Fc Profiling of Approved Anti-CD20 Antibodies

Measuring Target Protein Degradation in PBMCs: A KIF22 Pharmacodynamic Biomarker for the Clinic

Overcoming the Challenges in ADC Drug Product Development by Leveraging an Integrated Platform

Advancing Skin Research: A Scalable 3D Human Skin Organoid Model for Skin Barrier Function and Injury Screening

Leveraging In Vitro Permeation Testing: Emerging Roles in Discovery and Regulatory Science

AI-Ready, Lab-Proven: A New Standard for High-Throughput Antibody Characterization

Enhancing Clinical Predictability through Human Disease-relevant Preclinical Models in CNS and Muscle Drug Discovery

Visualizing Lipid Control of Drug Binding in Membrane Proteins at High Resolution

Structure is Strategy: Integrating Cryo‑EM, X‑ray, NMR and HDX‑MS for Precision Drug Discovery

New Approach Methodologies (NAMs): Key Considerations and Applications

From Clinical Data to Actionable Assets for Pharmaceutical R&D

Strategies to Optimize Commercialization of Oncology Treatments for Younger Adults

Patient Data: Opportunities for Rare Diseases, Cell and Gene Therapies, and Oncology

Trials and tribulations of drug development

Webinar Series: Early patient preferences for patient-focused drug development

Looking Beyond Survival Data: Understanding the Value of Non-OS Endpoints in Oncology Reimbursement Decision-Making

Cutting Edge Conversations: Discovering New Innovations in Oncology

Detecting Early Synaptic Failure in Prion Disease Using Organoid Models

Improving Preclinical Decision-Making in Obesity and CKD with Translational In Vivo Phenotyping

Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control

How to Avoid Expensive Redesign Cycles in Antibody Discovery

From Genetic Validation to Relevant Target Engagement: Small Molecule Inhibitor Binding to 17β-HSD13

Bridging Mouse Models and Human Inflammatory Bowel Disease: in vivo Pharmacology, Histology and Biomarkers

Improving Confidence in Thyroid Hormone Disruption Assessment Using a Novel Human-Relevant In Vitro Model

Accelerating Antibody Discovery: Integrating Microfluidics, HT Expression, and Early Developability Platform

Beyond Exposure: Integrating PK/PD for Translational Predictive Power

Screening the Unscreenable: Expanding the Reach of Drug Discovery

Fulfilling the Gap: Innovative Critical Reagents for Non-Human Primate Preclinical Studies

Advancing ADC Development: Leveraging AI and Translational Preclinical Models to Improve Clinical Predictability

Human iPSC-Derived Sensory Neurons for Functional Sensory Biology and Pharmacology Research

From Biopsy to Better Decisions: Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer

Accelerating Conjugation Process Development for Next-Generation ADCs: Key Considerations and Platform Strategies

High-Throughput-qPCR and Transcriptomics: Powering the Next Generation of Drug Discovery

Epigenomics at 360 in Liquid Biopsy: Approaches and Case Studies for Biomarker Discovery and Drug Development

The Sound of Science: Mapping the Tumor Microenvironment for Advanced Therapeutic Strategies

Precision in Human Biological Samples: Leveraging Regulatory Rigor and Deep Data for Advanced Disease Research

Next-Generation TCR-Like Antibodies With Improved Specificity Profiles

ADC Payload-Linker CMC Process Development Strategy

De-Risking Immunotherapy Targets with Next-Gen HLA Discovery Platforms

Photoreceptor Cell Therapy to Treat Advanced Retinal Degeneration

Clinical Applications of Optical Cerebral Blood Flow Imaging

ADCs on The Horizon: The Performance and Prospect of Cell Line Development Platform AmigoCHO

Building New Approach Methodologies for Angiogenesis and Vascularized Models

Using ALS Patient-Derived Motor Neurons to Study TDP-43 Mislocalization

Vevo Ask The Experts: Oncology Imaging

hiPSC-Cardiomyocyte Platforms Enabling Comprehensive Cardiac Toxicity and Drug Efficacy Evaluation

Protein-Protein Interaction (PPI) Landscape - Sequence-to-Affinity Heatmaps for High-Throughput Antibody Optimization

Combination Therapy for Glioblastoma: A Personalized, AI-Driven Approach

In Vivo panCAR Therapy Using Circular RNA for the Treatment of Autoimmune Disease

From Single Domain to Single B: Leveraging Biointron's Expertise for Antibody Discovery Success

Uniting biology and digital drug discovery to identify new therapeutic opportunities in neurodegeneration

Enhance Your Tissue Processing Efficiency with the STEMprep Tissue Dissociator

Reprogramming Mouse Fibroblasts Into Induced Cardiomyocytes: Age-Related, Metabolic, and Epigenetic Barriers

Novel Applications of the Cellular Thermal Shift Assay (CETSA) Provide New Insights for Drug Discovery

Vaccine-Boosting CAR T Cells Against Solid Tumors

Exploring the iPSC-Derived Neuronal-Glia Co-culture System: A Powerful Drug Discovery Platform for Studying Neurodegenerative Diseases

Integrating Regulatory Guidance and Sustainable Skin Procurement for Consistent Execution of In Vitro Permeation Testing

Launch Event: Propelling Boundaries - Innovative Technologies in Early Drug Discovery